Opinion
Video
Author(s):
Steven Nathan, MD, discusses how the findings from the study on oral nalbuphine extended release suggest that this treatment may offer an effective option for managing IPF-related cough, providing significant relief in terms of both frequency and severity, which could shift current management strategies by introducing a more targeted, pharmacologic approach to addressing one of the most challenging symptoms of IPF.
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.